Key statistics
On Thursday, Organon & Co (OGN:NYQ) closed at 14.89, 37.43% above the 52 week low of 10.84 set on Dec 06, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 14.77 |
---|---|
High | 15.05 |
Low | 14.75 |
Bid | 14.81 |
Offer | 15.04 |
Previous close | 14.73 |
Average volume | 2.73m |
---|---|
Shares outstanding | 257.54m |
Free float | 257.08m |
P/E (TTM) | 2.92 |
Market cap | 3.79bn USD |
EPS (TTM) | 5.04 USD |
Annual div (ADY) | 1.12 USD |
---|---|
Annual div yield (ADY) | 7.60% |
Div ex-date | Nov 12 2024 |
Div pay-date | Dec 12 2024 |
Data delayed at least 15 minutes, as of Nov 21 2024 21:10 GMT.
More ▼
- Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
- Organon Reports Results for the Third Quarter Ended September 30, 2024
- US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
- Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
- Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
- Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
- Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
More ▼